Health Trials

Fatty Liver and Pancreatic Steatosis

ConditionsExocrine Pancreatic InsufficiencyFatty Liver, NonalcoholicPancreatic Steatosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorMaria Marta Piskorz

About this trial

The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.

Participants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).

Eligibility criteria

Qualifiers

Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Disqualifiers

- Alcohol consumption >20 g/day in women, >30 g/day in men

Chronic hepatitis B or C infection

Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis

Hereditary hemochromatosis

Trial design

Treatments tested in this trial

  • Fecal elastase
  • Ecoendoscopy
  • Fibroscan
  • Serum cytokines

Treatment groups

No treatment groups listed

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Hospital de Clinicas Jose de San Martin Status unavailable 1119, Ciudad Autonoma de Buenos Aires, Buenos AiresArgentinaArgentina

Sponsors and collaborators

Maria Marta Piskorz

Lead sponsor

Hospital de Clinicas José de San Martín

Sponsor institution

Source ClinicalTrials.gov